* Inari Medical Inc NARI.OQ NARI.O is expected to show a
rise
in quarterly revenue when it reports results on April 30 for
the period ending March 31 2024
* The Irvine California-based company is expected to report
a
19.1% increase in revenue to $138.373 million from $116.17
million a year ago, according to the mean estimate from 9
analysts, based on LSEG data.The company's guidance on February
28 2024, for the period ended March 31, was for revenue of
$137.378 million.
* LSEG's mean analyst estimate for Inari Medical Inc is for
a
loss of 20 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Inari
Medical Inc
is $72.00, above its last closing price of $38.07.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 0.00 0.01 -0.08 Missed -1,433
.3
Sep. 30 2023 0.00 0.00 0.05 Beat 1,026.
1
Jun. 30 2023 -0.13 -0.13 0.04 Beat 131.6
Mar. 31 2023 -0.22 -0.23 -0.04 Beat 82.3
Dec. -0.17 -0.17 -0.11 Beat 35.8
31 2022
Sep. 30 2022 -0.26 -0.25 -0.19 Beat 25.1
Jun. 30 2022 -0.23 -0.23 -0.19 Beat 17.4
Mar. 31 2022 -0.09 -0.09 -0.06 Beat 34.5
This summary was machine generated April 26 at 21:29 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)